Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its Pacira BioSciences (NASDAQ:PCRX) stake by 360.1% in Q4 to 69,097 shares, representing about 0.16% of the company and valued at roughly $1.79 million.
• Q1 results and guidance: revenue grew about 5% to ~$177M, but FY2026 guidance of $745M–$770M was slightly below consensus, contributing to a negative market reaction and the stock trading down around 4.1%.
• Mixed analyst and insider signals: Needham raised its price target to $32 while the consensus remains a "Hold" with a $29.40 target, and insiders sold 32,261 shares in the past three months (insiders own 6.4%).

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 360.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,097 shares of the company's stock after buying an additional 54,079 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.16% of Pacira BioSciences worth $1,788,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hantz Financial Services Inc. raised its holdings in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock valued at $29,000 after buying an additional 721 shares during the period. Tidemark LLC purchased a new stake in shares of Pacira BioSciences in the 3rd quarter valued at $56,000. Strs Ohio purchased a new stake in shares of Pacira BioSciences in the 1st quarter valued at $75,000. iSAM Funds UK Ltd purchased a new stake in shares of Pacira BioSciences in the 3rd quarter valued at $80,000. Finally, Vestcor Inc purchased a new stake in shares of Pacira BioSciences in the 3rd quarter valued at $90,000. Hedge funds and other institutional investors own 99.73% of the company's stock.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Needham & Company raised its price target to $32 and maintained a Buy rating — this implies ~31.7% upside from the recent price and serves as a strong bullish analyst catalyst for investors focused on upside potential. Needham PT Raise
• Positive Sentiment: Q1 results beat expectations: revenue of ~$177M (+5% YoY) and EPS of $0.60 topped consensus, driven by commercial portfolio growth (including EXAPAREL volume growth). That operational beat supports near-term revenue trajectory and validates current demand. Q1 Press Release
• Positive Sentiment: Pipeline progress: Pacira advanced PCRX-201 into Phase II and completed enrollment in a Phase 3 shoulder OA study for ZILRETTA, keeping multiple clinical milestones on the calendar that could drive medium-term upside if readouts are positive. Pipeline & Guidance Summary
• Neutral Sentiment: Royal Bank of Canada raised its price target from $22 to $24 but kept a "sector perform" rating — the PT is only marginally changed relative to the market and signals a cautious stance despite the bump. RBC PT Update
• Neutral Sentiment: Earnings materials and the call highlighted "strong product growth" and provided detail on product mix and market dynamics — helpful context but not an immediate directional shock. Earnings Call Highlights
• Negative Sentiment: FY2026 revenue guidance of $745M–$770M sits slightly under consensus (~$761.5M at the time of the news), leaving the guidance a bit cautious and a potential near-term headwind if investors expected a clearer upside beat. Guidance Article
• Negative Sentiment: Overall market reaction is negative today (heavier-than-normal volume), reflecting investor caution as they reconcile the mixed signals: solid quarter and pipeline news vs. conservative-to-in-line guidance and at least one cautious analyst stance. Market Data

Analyst Ratings Changes

Several research firms recently issued reports on PCRX. HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Wall Street Zen downgraded Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 28th. Barclays cut their price objective on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating on the stock in a report on Thursday, March 26th. Royal Bank Of Canada boosted their price objective on Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a report on Friday. Finally, Needham & Company LLC boosted their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pacira BioSciences currently has a consensus rating of "Hold" and a consensus price target of $29.40.

Insider Buying and Selling

In related news, SVP Lauren Riker sold 4,000 shares of the business's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares of the company's stock, valued at $1,088,633.53. The trade was a 7.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Shawn Cross sold 12,941 shares of the business's stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the transaction, the chief financial officer directly owned 105,341 shares of the company's stock, valued at $2,650,379.56. The trade was a 10.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,261 shares of company stock valued at $785,850 in the last three months. 6.40% of the stock is owned by corporate insiders.

Pacira BioSciences Trading Down 4.1%

PCRX opened at $24.44 on Friday. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64. The stock has a market capitalization of $989.58 million, a price-to-earnings ratio of 162.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28. The business has a fifty day moving average price of $23.31 and a 200 day moving average price of $23.14.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Pacira BioSciences had a return on equity of 9.99% and a net margin of 0.70%.The company had revenue of $177.38 million for the quarter, compared to analyst estimates of $171.80 million. During the same period in the previous year, the firm earned $0.65 earnings per share. The company's revenue for the quarter was up 5.0% compared to the same quarter last year. Sell-side analysts expect that Pacira BioSciences, Inc. will post 1.85 earnings per share for the current fiscal year.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.